Plain-English translation of NCT06544343 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether adding remote monitoring visits — conducted by phone or video — alongside regular in-person doctor visits improves how well people manage a new immunosuppressive medication for autoimmune diseases like rheumatoid arthritis, lupus, or scleroderma. The study will compare patients who receive remote check-ins and extra support with those who receive standard care alone. Researchers believe that extra contact in the first few months after starting the medication may help people take it as prescribed, notice improvements faster, and feel better overall.
When people start a new immune-suppressing treatment, it can take weeks or months to know if it's working, and side effects often appear early on. Many patients struggle to stick with the medication or don't know what to expect during this critical period. This trial aims to see whether remote monitoring and closer support during those early months can help people stay on track and have better health outcomes.
You likely qualify if…
You likely don't qualify if…
Half of the participants will receive standard doctor visits plus additional remote check-ins (phone or video calls) and support services during the first few months after starting the new medication, while the other half will receive standard care only. You will be asked to attend appointments, participate in remote visits if assigned to that group, and may be asked to complete surveys about how well you're doing, how you're feeling, and whether you're taking the medication as prescribed. The study will track your health outcomes and quality of life over the initial treatment period.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Italy